ARTICLE | Preclinical News
Heterologous, autologous cell therapy could treat hemophilia B
May 3, 2018 11:19 PM UTC
A study published in Cell Reports from researchers at Salk Institute for Biological Studies suggests that heterologous and autologous cell therapy could help treat hemophilia B.
Hemophilia B is characterized by a systemic lack of clotting Factor IX. Recombinant human Factor IX supplements used to treat the disease require frequent IV administration and become less effective over time...
BCIQ Company Profiles
BCIQ Target Profiles